Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.77 |
| ▸ | AXL | P30530 | 6/20 | 0.77 |
| ▸ | KDR | P35968 | 4/20 | 0.77 |
| ▸ | MERTK | Q12866 | 3/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.64 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.64 |
| ▸ | FLT1 | P17948 | 3/20 | 0.64 |
| ▸ | FLT3 | P36888 | 5/20 | 0.63 |
| ▸ | RET | P07949 | 3/20 | 0.63 |
| ▸ | KIT | P10721 | 3/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.61 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31412953 | 0.91 | MET (0.65) | METAXLKDRMERTKFLT3 | |
| SCHEMBL16070076 | 0.87 | AURKB (0.84) | METAXLKDRMERTKPDGFRA | |
| Exelixis SCHEMBL371899 | 0.87 | MET (1.00) | METAXLKDRMERTKPDGFRA | |
| Exelixis SCHEMBL29693473 | 0.87 | MET (1.00) | METAXLKDRMERTKPDGFRA | |
| SCHEMBL19373358 | 0.86 | MET (0.88) | METAXLKDRMERTKPDGFRA | |
| SCHEMBL24444658 | 0.85 | MET (0.69) | METAXLKDRMERTKPDGFRA | |
| SCHEMBL5056203 | 0.85 | PDGFRA (0.72) | METAXLKDRPDGFRAFLT3 | |
| SCHEMBL469293 | 0.84 | MET (0.75) | METAXLKDRMERTKPDGFRA | |
| SCHEMBL16069980 | 0.83 | MET (0.82) | METAXLKDRMERTKPDGFRA | |
| SCHEMBL469347 | 0.83 | MET (0.84) | METAXLKDRMERTKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552695-A2 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-05-14 | — | — | EP | disclosed |
| CN-119841776-A | Tyrosine kinase inhibitors and uses thereof | 华上生技医药股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | Great Novel Therapeutics Biotech & Medicals Corporation (TW) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250120967-A1 | TYROSINE KINASES INHIBITORS AND USES THEREOF | LCK, LTK, HIF1AN | MET 592/4885AXL 339/4885KDR 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.